Phase 3 Trial of ION-1 Will Continue

Share

Follow Us

Print this page

Gilead To Continue Phase 3 Trial Of Hepatitis C Compound Without Change

By RTT News,  March 26, 2013

RTTNews.com) – Biopharmaceutical company Gilead Sciences Inc. ( GILD ) Tuesday said the phase 3 trial ION-1, evaluating once-daily fixed-dose combination of the nucleotide sofosbuvir and the NS5A inhibitor ledipasvir with and without ribavirin for 12 or 24 weeks among treatment-naïve genotype 1 patients with hepatitis C virus infection should continue without any modification.

Continue reading this entire article:
http://www.nasdaq.com/article/gilead-to-continue-phase-3-trial-of-hepatitis-c-compound-without-change-20130326-00437#.UVRCBUczJhp

Download Our Free Reports

Inside you'll discover:

• Things You May Not Know About Hepatitis C
• 7 Liver Detox SUPER Foods Your Doctor Isn't Telling You About
• 5 Dangerous Foods That Will Wreak Havoc On Your Liver
• A free "Mystery" Gift Valued at $9.99

Email address

Download Now

You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.